| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 7
| Issue : 1 | Page : 41-43 |
|
|
Exendin-4 for Parkinson's disease
Felipe de Jesús Esparza-Salazar, Alma Rosa Lezama-Toledo, Germán Rivera-Monroy, Cesario V Borlongan
Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
Correspondence Address:
Cesario V Borlongan
Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL 33612
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/bc.bc_21_21
|
|
|
This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
